|1.||DeNardo, Sally J: 4 articles (03/2007 - 08/2002)|
|2.||DeNardo, Gerald L: 4 articles (03/2007 - 08/2002)|
|3.||Miers, Laird A: 3 articles (03/2007 - 08/2002)|
|4.||Natarajan, Arutselvan: 3 articles (03/2007 - 10/2005)|
|5.||Ivkov, Robert: 2 articles (03/2007 - 10/2005)|
|6.||Gruettner, Cordula: 2 articles (03/2007 - 10/2005)|
|7.||Adamson, Grete N: 2 articles (03/2007 - 10/2005)|
|8.||Foreman, Allan R: 1 article (03/2007)|
|9.||Wang, Xiaobing: 1 article (01/2007)|
|10.||Lam, Kit S: 1 article (01/2007)|
|1.||Breast Neoplasms (Breast Cancer)
05/01/1997 - "Three patients with incurable metastatic breast cancer received 90Y/111In-DOTA-peptide-ChL6 for 5 pharmacokinetics/dosimetry studies and one of these patients also received 2 therapy doses. "
01/01/2007 - "One of these peptide substrates (rqYKYkf) was used to link the DOTA chelate to ChL6, a monoclonal antibody known to target breast cancer. "
12/01/2005 - "Twenty-nine NHL patients treated with radiolabeled-Lym-1 and 9 breast cancer patients, the reference group, treated with radiolabeled ChL6, BrE-3, or m170, were analyzed using X-ray computer tomography (CT) splenic images obtained before and after RIT. "
05/01/1997 - "The biologically active, antiadenocarcinoma monoclonal antibody chimeric L6 (ChL6) was labeled with 131I and administered in cycles to patients with metastatic breast cancer who had failed standard therapy. "
01/01/1994 - "131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. "
01/01/1994 - "In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. "
01/01/1993 - "ChL6 was administered intravenously to 18 patients with advanced cancer as a single, 4-16 infusion in doses ranging from 350 mg/m2 to 700 mg/m2. "
04/01/1999 - "Biodistribution experiments performed on nude mice with KS Y-1 xenografts demonstrate tumor targeting by ChL6. "
04/01/1999 - "Because ChL6 has been noted to bind vascular endothelium, our hypothesis was that ChL6 will recognize and bind KS tumors making this a potentially useful antibody for the treatment of KS with radioimmunotherapy. "
01/01/1993 - "Platelet count and absolute leukocyte count fell immediately after treatment, but returned to pretreatment levels by day 7. Localization of chL6 to tumor cells in vivo was seen at 350 mg/m2 and "saturation" at 700 mg/m2 and 350 mg/m2 per week x 4. The pharmacokinetics of this antibody appeared similar to its murine analogue. "
|3.||Prostatic Neoplasms (Prostate Cancer)
05/01/1995 - "Indium-111 and yttrium-90 were attached to an anti-adenocarcinoma chimeric L6 (ChL6) monoclonal antibody (MAb) after pre-chelation to the DOTA-peptide-NCS and the desired neutral radiochelates were obtained by purification. "
10/01/1999 - "Lym-1, an anti-lymphoma mouse IgG2 alpha chimeric L6 (ChL6), an anti-adenocarcinoma mouse IgG2 alpha-human IgG1 chimera, and the immunoconjugate 2IT-BAD-Lym-1 were examined for stability following storage. "
|5.||Chromosomal Instability (Chromosome Stability)
|1.||Immunoglobulin G (IgG)
|2.||Surface Antigens (Surface Antigen)
|7.||monoclonal antibody 2IT-BAD-Lym-1
|8.||ferric oxide (iron oxide)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)